NCT02936778

Brief Summary

This study will prospectively assess the impact and relevance of several risk factors for children with severe acute asthma (SAA) or acute wheeze that have been identified in retrospective studies. Secondary we will assess short-term medical and psychosocial functioning in patient (and parents) admitted to a PICU for SAA/acute wheeze versus a control group admitted to a MC for SAA/acute wheeze.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
221

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2016

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2016

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 12, 2016

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 18, 2016

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2019

Completed
Last Updated

May 23, 2019

Status Verified

May 1, 2019

Enrollment Period

2.7 years

First QC Date

October 12, 2016

Last Update Submit

May 21, 2019

Conditions

Keywords

Short-term medical and psychosocial functioning

Outcome Measures

Primary Outcomes (1)

  • Undertreatment in children admitted to a PICU with a diagnosis of SAA/acute wheeze

    Undertreatment is defined as: Patient is not using inhaled corticosteroids (ICS), or Patient is using ICS \< 7 days (counting from moment of admission to emergency department) according to treatment plan, or Patient is not using ICS according tot treatment plan.

    Within the time of admission on the PICU/MC, preferably within 48 hours and during follow up after 3-6 months

Secondary Outcomes (5)

  • Exposure to triggers (single or combined)

    Within the time of admission on the PICU/MC, preferably within 24 hours

  • Socio-economic status

    Within the time of admission on the PICU/MC

  • Frequency of previous asthma-related hospital admissions and/or PICU admissions.

    Within the time of admission on the PICU/MC and during follow up after 3-6 months

  • Severity of disease, defined using the GINA criteria for stepwise management of asthma.

    Within the time of admission on the PICU/MC, preferably within 48 hours and during follow up after 3-6 months

  • Distribution of ADRB2-receptor polymorphisms compared to non-SAA population.

    Through study completion, preferably within the time of admission on the PICU/MC

Study Arms (2)

PICU (= case group)

Children aged 2-18 years admitted to a Paediatric Intensive Care Unit in the Netherlands, with a diagnosis of acute wheeze or SAA.

MC (= control group)

Children aged 2-18 years admitted to a Medium Care in the Netherlands, with a diagnosis of acute wheeze or SAA.

Eligibility Criteria

Age2 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodProbability Sample
Study Population

Children aged 2-18 years admitted to a Medium Care or Paediatric Intensive Care Unit in the Netherlands, with a diagnosis of acute wheeze or SAA.

You may qualify if:

  • Between 2 and 18 years of age
  • Admission to a PICU for SAA or acute wheeze or admission to a MC for SAA or acute wheeze

You may not qualify if:

  • Patient is outside of specified age range
  • Down's Syndrome
  • Congenital/acquired heart defect that interferes with normal SAA treatment
  • Congenital/acquired airway defect (tracheomalacia/bronchomalacia)
  • Primary/secondary immunodeficiency
  • Pre-existing chronic pulmonary condition, known to mimic asthma: Cystic Fibrosis, Bronchopulmonary dysplasia, Bronchiolitis obliterans
  • If both parents are not able to speak the Dutch language

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Erasmus MC

Rotterdam, South Holland, 3000WB, Netherlands

Location

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr.

Study Record Dates

First Submitted

October 12, 2016

First Posted

October 18, 2016

Study Start

August 1, 2016

Primary Completion

April 1, 2019

Study Completion

April 1, 2019

Last Updated

May 23, 2019

Record last verified: 2019-05

Locations